Ieramilimab
experimental cancer drug
Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.
Ieramilimab's first clinical trial is a Phase I in patients with various solid tumors, in combination with spartalizumab (PDR001), an anti-PD-1 monoclonal antibody has been completed. Recruiting for a phase 2 study in combination with spartalizumab for the treatment of metastatic melanoma is underway.
The public source identifies “Ieramilimab” as experimental cancer drug. This brief keeps that definition visible, then builds a research path around Ieramilimab, experimental and cancer.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Ieramilimab”, the useful work is to connect “experimental cancer drug” to the records capable of establishing context and consequence.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 2, 2025. The linked authority identifier is Q25111469. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2015.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Ieramilimab”, its source revision and the description used here.
- Expand the search: follow Ieramilimab primary sources, Ieramilimab archive and Ieramilimab research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Ieramilimab”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Ieramilimab” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.